# Ikris Pharma Network > Ikris Pharma Network is an international pharmaceutical service company with a global presence spanning 150+ countries and over 30 years in business. It connects pharmaceutical companies, researchers, healthcare professionals, and patients worldwide—specializing in access to hard-to-find, unregistered, and life-saving medicines through named patient programs, clinical trial sourcing, generic medicine supply, real-world data, and managed access programs. Ikris focuses on bridging gaps in global medicine access, with particular strength in rare disease treatments, oncology, and reference listed drug (RLD) sourcing. The company maintains 24/7 support (365 days a year), rapid response times, world-class quality standards, and cold chain shipment capability, serving 10,000+ patients with a database of 15,000+ medicines. Key facts: - Countries served: 150+ - Years in business: 30+ - Medicines in database: 15,000+ - Patients served: 10,000+ - Founded: August 2014, by Mr. Praveen (Parveen) Sikri - Offices: India (Noida), Bulgaria (Sofia), Hong Kong; earlier entity in Belgium (Ikris Pharma International) Contact: - Email: info@ikrispharmanetwork.com - Toll free: 1800 1200 365 (also 18008891064 noted for Real World Data) - Mobile/WhatsApp: +91-9654860915 - Careers: +91-9220822566 - India Office: 905, I-Thum Business Park, Block A-40, Sector-62, Noida, Uttar Pradesh 201301; Phone 8527273611, +91-9310090915 - Bulgaria Office: IKRIS PHARMA NETWORK Ltd. 1202, Sofia, str. George Washington 24 (https://ikrispharmanetwork.bg) - Hong Kong Office: Unit 809, 8/F, Brill Plaza, 84 To Kwa Wan Road, 3007218, Hong Kong - LinkedIn: https://in.linkedin.com/company/ikris-pharma-network - Instagram: https://www.instagram.com/ikrispharmanetwork - Twitter/X: https://twitter.com/IkrisPharma - Facebook: https://www.facebook.com/Ikrispharmanetwork --- ## Home URL: https://ikrispharmanetwork.com/ Tagline: "We help you Connect to the World." Overview: Ikris Pharma Network is an internationally acclaimed pharmaceutical service company with a strong and extensive global presence. Renowned for its pharmaceutical services, the company operates across numerous countries, making its expertise and solutions available to clients and patients worldwide. It positions itself as a leader in the global pharmaceutical industry, built on innovation, quality, and a commitment to advancing healthcare. Global Presence: Ikris maintains a global network reaching diverse markets, fostering innovation and meeting customer needs worldwide through a network of subsidiaries and partners. Highlights include 24/7 support 365 days a year, rapid response time, world-class quality standards, and specialty in cold chain shipments. Core service areas surfaced on the home page: Named Patient Management, Indian Generic Medicines, and Clinical Trial Sourcing. The home page also promotes the Ikris Health+ App for accessing hard-to-find medicines. --- ## Company / About Us URL: https://ikrispharmanetwork.com/about-us About: Ikris Pharma Network is a global pharmaceutical company founded with a commitment to improving global healthcare accessibility. It describes itself as more than a pharmaceutical services provider—a partner in ensuring essential medicines reach those who need them most, believing that timely access to medication matters regardless of geographical or logistical challenges. Vision: Ikris frames every patient as a unique journey toward health and wellness, providing the right medication at the right time. The company sees its role as going beyond dispensing medicines—instilling hope, fostering resilience, and making a real difference. Mission: To provide patients and healthcare personnel within a country an independent global network, plus future products and services, to satisfy unmet medical needs where current treatment is either unavailable or all other options have been exhausted. Values: 1. Creating Valuable Partnerships — forging strong partnerships to foster collaboration, accelerate healthcare innovation, and address healthcare disparities. 2. Creating a Meaningful Impact — using innovation to address unmet medical needs, enhance treatment efficacy, and improve patient experiences. 3. Pursuit for Excellence — working with determination to push boundaries and strive for excellence. 4. Embracing Diversity and Inclusion — fostering an inclusive environment where everyone feels welcome and respected. Timeline: - 2014 (August): Ikris founded by Mr. Parveen Sikri after nearly three decades in the pharmaceutical industry, including roles at multinational and top Indian pharmaceutical companies. - 2015 (June): Strong focus on Managed Access Programs under the vision of "Transforming Lives through Networking." - 2016 (June): Global expansion with a new entity in Belgium—Ikris Pharma International, Belgium—receiving a GDP certificate from the Belgian Federal Agency for Medicines and Health Products with a certified pharmaceutical warehouse. - 2017 (June): Built a robust presence in international healthcare exports, expanding treatment options for patients who had exhausted other options. - 2018–2019 (June): Served numerous patients with rare diseases and supported affected communities. - 2020 (June): Contributed to frontline COVID efforts by ensuring access to crucial medications and supplying several countries. - 2021 (June): Entered innovator-sample sourcing (single/multiple batches of specific quantities) for clinical trials and bioequivalence studies; continued growth in Named Patient Management (NPM) and rare disease segments. - 2022 onward: Became (per the company) the biggest Named Patient Import medicine supplier, partnering with companies in oncology and rare disease such as Recordati Rare Diseases, PTC Therapeutics, BioMarin, Sarepta Therapeutics, Servier Pharmaceuticals, and Alexion. Leadership and team: - Mr. Praveen Sikri — Founder & CEO - Mrs. Sangeeta Sikri — Women Welfare Officer - Bharat Sikri — Global Project Manager - Maneesha Singh — Global Accounts Manager - Poonam Bisht — Head, Logistics - Jyoti Rawat — Head, Accounts - Vidhu Saxena — Market Access Manager - Rajesh Joshi — Vice President, Commercial Head - Brajesh Kumar — Head, Digital Marketing & IT --- ## Partners URL: https://ikrispharmanetwork.com/partners Ikris collaborates with globally recognized pharmaceutical organizations to ensure patients receive authentic, high-quality medicines and gain access to hard-to-find therapies. Most partnerships enable access for Indian patients (and in some cases neighboring countries) through the Named-Patient Import pathway. Partners: - Recordati Rare Diseases — Ikris helps patients in India, Nepal, Pakistan, and Sri Lanka access Recordati / Orphan Europe products via strategic alliances and an exclusive distribution agreement. (recordati.com) - PTC Therapeutics — Ikris is authorized to provide access to PTC medicines for Indian patients through Named-Patient Import. (ptcbio.com) - Servier Pharmaceuticals — Ikris is authorized to provide access to Servier medicines for Indian patients through Named-Patient Import. (servier.com) - BioMarin — Founded in 1997, a global biotechnology company focused on genetic discovery and targeted therapies. Ikris is authorized to provide access to BioMarin medicines for Indian patients through Named-Patient Import. (biomarin.com) - Sarepta Therapeutics — Focused on precision genetic medicine. Ikris is authorized to provide access for Indian patients through Named-Patient Import. (sarepta.com) - Alexion Pharmaceuticals — Ikris is authorized to provide access to Asfotase Alfa for Indian patients through Named-Patient Import. (alexion.com) - Santhera Pharmaceuticals — Focused on rare and neuromuscular conditions. Ikris is officially authorized to facilitate patient access to Santhera medicines for Duchenne Muscular Dystrophy (DMD) in India through the Named-Patient Import pathway. (santhera.com) - Gilead Sciences — Ikris is authorized to support patient access to specific therapies for HR+/HER2- metastatic breast cancer and metastatic triple-negative breast cancer in India through the Named-Patient Import pathway. (gilead.com) Partnership Program: Ikris invites collaboration on research and global healthcare impact. Contact: info@ikrispharmanetwork.com. --- ## Service: Named Patient Management URL: https://ikrispharmanetwork.com/services/named-patient-management Positioning: "Your Health, Our Priority. Your Access Our Promise." Ikris works to overcome regulatory, logistical, and geographic barriers to provide patients with the medicines they require. Specialty medicines / legal access: - Helps patients and healthcare professionals access life-saving medications not available or registered in their home country. - Major therapeutic areas covered: Oncology, Hepatology, Neurology, Transplant, Hematology, Immunology, Nephrology. - The team is trained in pharmacovigilance, ABAC (anti-bribery/anti-corruption), patient and data privacy, and business compliance. - Includes an experienced team of therapy specialists with domain knowledge. Rare disease medicines: - Ikris aims to transform the lives of patients living with rare diseases. - Partners with global pharmaceutical companies focused on discovery, development, and commercialization of therapies for rare diseases. - Provides access to treatments for rare diseases including Duchenne Muscular Dystrophy, Lysosomal Disorders, Organic Acidemias, Urea Cycle Disorders, Acute Intermittent Porphyria, MPS IV A, MPS VI, Hypophosphatasia, PKU, BH4 Deficiency, Batten Disease, and more. --- ## Service: Clinical Trial Sourcing URL: https://ikrispharmanetwork.com/services/clinical-trial-sourcing Positioning: Proven excellence in clinical trial sourcing. Ikris follows a strategic approach to ensure trial continuity, mitigate risks from drug shortages or supply chain disruptions, and guarantee that all components are in the right place at the right time. Reference Listed Drugs (RLDs): - Extensive experience and knowledge of each country's regulatory requirements for sourcing products from authorized, reliable global suppliers and partners. - Helps clients find the appropriate RLD from a specific country of origin to support product development programs. - Can source and supply RLDs as required (specific batches and expiries) on an international scale. - Experience with cold chain shipping and international customs to keep temperature-sensitive study drugs within required temperature ranges to clinical trial facilities. Clinical Trial Supply: - Stringent operating procedures to guarantee quality, with a validated supplier network. - Streamlined supply for timely delivery, with tracking to get the study drug to the right place at the right time. - Specialized clinical trial materials supply using a global sourcing network, experience, and infrastructure. --- ## Service: Indian Generic Medicines URL: https://ikrispharmanetwork.com/services/indian-generic-medicines Positioning: "Bringing India's Generic Drugs to the World's Doorstep." India is positioned as the "Pharmacy of the World," producing and distributing high-quality, cost-effective drugs globally. Affordable healthcare solutions: - Exports medicinal products to over 150+ countries. - Delivers trusted, quality generic medicines across the pharmaceutical market. - Assured delivery of quality generic medicines from India to patients, hospitals, resellers, and pharmacies worldwide. - Established network with leading, best-in-class generic medicine manufacturers from India. Contract manufacturing: - Direct sourcing from manufacturers, enabling large batches with good shelf life. - Fast network, prompt solutions, and competitive prices. - Less expensive alternatives to brand-name drugs without compromising quality or effectiveness. --- ## Service: Real World Data URL: https://ikrispharmanetwork.com/services/real-world-data Positioning: "Collecting, Real-World. Data." From real-life care to decision-ready market access intelligence—ethically, compliantly, at global scale. Ikris frames clinical trials as just one chapter in a medicine's story; collecting Real-World Data (RWD) through a Managed Access Program offers a unique window, especially for medicines not yet licensed. Who benefits: - Pharmaceutical innovator companies — identify early demand before product launch and sharpen evidence plans. - Market access and consulting firms — gain credible inputs for forecasting, pricing, and policy strategy. - Regulators and NGOs — understand therapy gaps and equity issues to support advocacy and reimbursement frameworks. - Distributors and access programs — spot new growth markets, emerging prescriber demand, and unmet needs in real time. What Ikris offers: - Real-world observation for unlicensed or early-access therapies via Managed/Expanded/Named Patient Programs (where permitted), yielding early pragmatic insights. - Access-program expertise embedding low-burden, compliant RWD capture within MAP/EAP/NPP programs. - Therapeutic depth across multiple therapeutic areas and care settings. - Reimbursement and market strategy support; RWD informs pricing, access, and market positioning. How Ikris supports the journey: - Actionable insights — analytics team transforms raw entries into clear strategic reports. - Compliance first — every dataset is anonymized, ethically collected, and aligned with international standards. - Contact for RWD: info@ikrispharmanetwork.com; Toll free 18008891064. --- ## Product: Triokris (Trientine Hydrochloride Capsules USP 250 mg) URL: https://ikrispharmanetwork.com/our-products/triokris Overview: Triokris is a copper-chelating agent indicated for the treatment of Wilson's Disease, especially in patients who cannot tolerate D-Penicillamine. It is manufactured in a USFDA-approved facility and distributed by Ikris Pharma Network, which positions itself as a trusted Trientine supplier in India offering global access to Trientine 250 mg. About Wilson's Disease: A rare genetic disorder of copper metabolism causing toxic copper accumulation in the liver, brain, and other organs. Early diagnosis and lifelong treatment are essential. Trientine Hydrochloride is a key therapy when D-Penicillamine is not tolerated. Clinical benefits: - Effective in hepatic and neurological manifestations of Wilson's Disease. - Lower risk of hypersensitivity compared to D-Penicillamine. - Improves long-term clinical outcomes with continuous therapy. - Well tolerated by patients requiring lifelong copper management. Dosage and administration: - Adults and adolescents: usual dose 750–1500 mg/day, divided into 2–4 doses. - Take on an empty stomach (at least 1 hour before or 2 hours after meals). - Avoid taking with iron, zinc, calcium, or magnesium supplements at the same time (they interfere with absorption). - Dosage must be individualized and supervised by a physician. Safety and precautions: - Not interchangeable with D-Penicillamine. - Contraindicated in patients with known hypersensitivity to Trientine. - Regular monitoring required (liver function tests, blood counts, serum copper, ceruloplasmin levels). - May cause anemia due to iron depletion—monitor closely. Product information: - Active ingredient: Trientine Hydrochloride USP - Strength: 250 mg capsules - Presentation: 100 capsules per bottle - Storage: store at 25°C, protected from moisture and light - Manufacturing: USFDA-approved facility; supplied via WHO-GDP and ISO-certified logistics Note: This product information is summarized from the company's marketing page. It is not medical advice; treatment decisions should be made with a qualified physician. --- ## Ikris Health+ App URL: https://ikrispharmanetwork.com/ikris-health-plus A user-friendly mobile app offering a comprehensive global medicine database to simplify access to vital medical information and hard-to-find medicines, putting essential data and support at users' fingertips. --- ## News & Updates URL: https://ikrispharmanetwork.com/news-and-updates Company news and developments in the medical and pharmaceutical field. Recent articles include: - Premium Hematology Medicine Supplier for Hospitals, Importers & Wholesalers (2026-06-05) — https://ikrispharmanetwork.com/article/premium-hematology-medicine-supplier-for-hospitals-importers-wholesalers - Best Oncology Medicine Supplier in India – Global Oncology Product Exporter (2026-05-29) — https://ikrispharmanetwork.com/article/best-oncology-medicine-supplier-in-india-global-oncology-product-exporter - List of Medicines Available for Export from India (2026-05-22) — https://ikrispharmanetwork.com/article/list-of-medicines-available-for-export-from-india - Named Patient Program in India: How to Import Unapproved Medicines — https://ikrispharmanetwork.com/article/named-patient-program-in-india-how-to-import-unapproved-medicines - Global RLD & Innovator Drug Sourcing for Clinical Trials / BA-BE Studies — https://ikrispharmanetwork.com/article/global-rld-innovator-drug-sourcing-for-clinical-trials-ba-be-studies - Pharmaceutical Exporter to Brazil and Nigeria from India 2025 — https://ikrispharmanetwork.com/article/pharmaceutical-exporter-to-brazil-and-nigeria-from-india-2025-growth-supply-compliance-insights - Who Supplies Trientine Hydrochloride Capsules in India? — https://ikrispharmanetwork.com/article/who-supplies-trientine-hydrochloride-capsules-in-india --- ## Other Pages - Contact Us — https://ikrispharmanetwork.com/contact-us - Careers — https://ikrispharmanetwork.com/career (careers contact: +91-9220822566) - Resources — https://ikrispharmanetwork.com/resources - Privacy Policy — https://ikrispharmanetwork.com/privacy-policy - Disclaimer — https://ikrispharmanetwork.com/disclaimer - Adverse Event Reporting — https://ikrispharmanetwork.com/adverse-event-reporting (pharmacovigilance / reporting of adverse drug events)